{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 464383569
<!-- Monoclonal antibody data -->
| type = mab
| mab_type = mab
| source = zu
| target = [[IFN-Î±]]
<!-- Clinical data -->
| tradename =  
| pregnancy_AU =  
| pregnancy_US =  
| pregnancy_category =  
| legal_AU =  
| legal_CA =  
| legal_UK =  
| legal_US =  
| legal_status =  
| routes_of_administration =  
<!-- Pharmacokinetic data -->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =  
<!-- Identifiers -->
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = none
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 948570-30-7
| ATC_prefix = none
| ATC_suffix =  
| PubChem =  
| KEGG = D09662
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = LDO2FIQ61I
<!-- Chemical data -->
| chemical_formula =
| C=6486 | H=9990 | N=1722 | O=2026 | S=44
| molecular_weight = 145.9 kg/mol
}}
'''Rontalizumab''' is a [[humanized]] [[monoclonal antibody]]<ref>[http://www.who.int/medicines/publications/druginformation/innlists/PLFinal101.pdf WHO Drug Information]</ref> being developed by [[Genentech]].<ref>[http://www.gene.com/gene/pipeline/status/immunology/rhumab-ifnalpha/ Genentech: Rontalizumab (rhuMAb IFN alpha)]</ref> {{as of|2009|11}}, it is being investigated in a [[clinical trial]] for the treatment of [[systemic lupus erythematosus]].<ref>{{ClinicalTrialsGov|NCT00962832|A Study to Evaluate the Efficacy and Safety of Rontalizumab in Patients With Moderately to Severely Active Systemic Lupus Erythematosus (ROSE)}}</ref>

==References==
{{Reflist}}

{{Monoclonals for immune system}}
{{Cytokine receptor modulators}}

[[Category:Monoclonal antibodies]]


{{monoclonal-antibody-stub}}
{{antineoplastic-drug-stub}}